Subscribe

News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Subscribe

|Videos|April 16, 2020

Modernizing Drug Development in the Face of the COVID-19 Pandemic

Author(s)Cognizant

Drug development paradigms need to change in order to quickly bring new therapeutics to patients affected by pandemics like COVID-19.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Launch is Just the Beginning: Rare Disease Care Requires Durability

ByBansi Nagji, CEO, PANTHERx Rare

July 7th 2026

Sponsored

Woman with short straight blonde hair, black glasses, and blue shirt smiles in front of an Acumetis blue background

Access by Design: Embedding Market Access Thinking Across the Drug Development Lifecycle

ByEsther Nzenza, Senior Partner and Global Head of Value and Access,Acumetis

Published: June 26th 2026 | Updated: June 30th 2026

Sponsored

A man with light hair and blue eyes stands in front of a LogiPharma background in a gray suit and white collared shirt

Improving Global Pharma Operations with Data

ByChristoph Bamert, Chief Sales Officer,ELPRO-BUCHS AG, Switzerland

June 10th 2026

Sponsored

Miranda Delatore, CoverMyMeds, on how a connected specialty access and affordability ecosystem is eliminating delays, reducing friction, and transforming the way biopharma manufacturers get patients started on life-changing therapies faster than ever before.

What Specialty Access Looks Like When It’s Built to Scale

ByMiranda Delatore, DNP, RN, NEA‑BC, CoverMyMeds

June 9th 2026

Sponsored

Two men, one with brown hair, is gesturing towards a bald man in conversation. They are both wearing Inizio Engage t-shirts.

An End-to-End Approach to Specialty Patient Services

ByJason Rains, Senior Vice President, Patient Access,Randy Quist, Vice President, Field Reimbursement,Inizio Engage

June 3rd 2026

Sponsored

Trending on PharmExec

Novartis to Layoff 322 NJ Employees: Report

Launch is Just the Beginning: Rare Disease Care Requires Durability

“AI as Reinvention”: Transforming the Business of Medicine

Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement

Pharma at a Political Crossroads